Drug |
Effective date for reimbursement |
Funding stream |
Approved Indications |
Abiraterone |
June 2012 |
PCRS Community Schemes (PCRS) |
Treatment of mCRPC which has progressed on or after a docetaxel-based chemotherapy regimen |
Abiraterone |
May 2015 |
PCRS |
Treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. |
Acalabrutinib (tablets) |
July 2023 |
PCRS |
As monotherapy for the treatment of previously untreated CLL in the presence of 17p deletion or TP53 mutation in adult patients unsuitable for chemoimmunotherapy.
As monotherapy for the treatment of adult patients with CLL who have received at least one prior therapy. |
Acalabrutinib
(capsules)
|
October 2021 |
PCRS |
As monotherapy for the treatment of previously untreated CLL in the presence of 17p deletion or TP53 mutation in adult patients unsuitable for chemoimmunotherapy
As monotherapy for the treatment of adult patients with CLL who have received at least one prior therapy
|
Afatinib |
January 2014 |
PCRS |
Afatinib as monotherapy is indicated for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s) |
Aflibercept |
April 2014 |
Individual hospital budgets |
In combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is approved for use in adults with metastatic colorectal cancer that is resistant to or has progressed after an oxoliplatin-containing regimen. |
Alectinib
|
November 2017 |
PCRS |
Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib |
Alectinib
|
June 2019 |
PCRS |
As monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC |
Apalutamide
|
April 2023 |
PCRS |
For the treatment of patients with metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy. |
Apalutamide
|
August 2021 |
PCRS |
Treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease |
Atezolizumab |
March 2022 |
ODMS |
Atezolizumab in combination with carboplatin and etoposide is indicated for first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
|
Atezolizumab |
March 2022 |
ODMS |
In combination with nab-PACLitaxel for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease
|
Atezolizumab |
July 2021 |
ODMS |
Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumours have a PD-L1 expression ≥5%
|
Atezolizumab |
October 2021 |
ODMS |
As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PDL1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltratingimmune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC
|
Atezolizumab |
March 2021 |
ODMS |
Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) after prior platinum-containing chemotherapy
|
Atezolizumab |
March 2019 |
ODMS |
Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.
|
Avelumab
|
May 2019 |
ODMS |
Treatment of adult patients with metastatic Merkel cell carcinoma who have received 1 or more lines of chemotherapy for metastatic disease |
Avelumab |
September 2022 |
ODMS |
First-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum based chemotherapy[HD1]
|
Axicabtagene ciloleucel
|
April 2022 |
ODMS |
For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy |
Axitinib |
March 2013 |
PCRS |
Treatment of adult patients with advanced RCC after failure, on a previous line of therapy, i.e. treatment with SUNItinib, or a cytokine. |
Blinatumomab |
May 2022 |
ODMS |
For the treatment of paediatric patients aged 1 years or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (ALL) as part of consolidation therapy. |
Blinatumomab |
February 2021 |
ODMS |
As monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% |
Blinatumomab |
May 2019 |
ODMS |
Treatment of adult patients with relapsed or refractory B cell precursor (BCP) Philadelphia chromosome negative acute lymphoblastic leukaemia (ALL) who have received no prior salvage treatment for relapsed/refractory (R/R) disease and are considered eligible for transplant (i.e. as a bridge-to-transplant) |
Blinatumomab |
May 2019
|
ODMS |
As monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation |
Bosutinib |
January 2014 |
PCRS |
Treatment of adult patients with chronic phase, accelerated phase, and blast phase Ph+CML previously treated with one or more TKI(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. |
Brentuximab vedotin |
December 2022 |
ODMS |
Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy. |
Brentuximab vedotin |
December 2022 |
ODMS |
Treatment of adult patients with CD30+ Hodgkins Lymphoma (HL) at increased risk of relapse or progression following an autologous haematopoietic stem cell transplant (ASCT). |
Brentuximab vedotin |
December 2022 |
ODMS |
In combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL). |
Brentuximab vedotin |
August 2014 |
ODMS |
The treatment of adults with
- Relapsed or refractory CD30 positive Hodgkin Lymphoma who have
o failed at least one autologous stem cell transplant (ASCT) or
o at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.
- Relapsed or refractory systemic anaplastic large cell lymphoma.
|
Brentuximab vedotin and Bendamustine |
October 2019 |
ODMS |
Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL)
|
Brentuximab vedotin and etoposide, CISplatin, cytarabine (ESHAP) |
September 2019 |
ODMS |
Treatment of adult patients with relapsed/refractory CD30+ Hodgkin’s lymphoma.
|
Brentuximab vedotin, and CARBOplatin, etoposide, ifosfamide (ICE) |
September 2019 |
ODMS |
Treatment of adult patients with relapsed/refractory CD30+ Hodgkin’s lymphoma.
|
Brigatinib |
October 2020 |
PCRS |
Monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor |
Brigatinib |
June 2019 |
PCRS |
For the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib |
Cabazitaxel |
March 2013 |
ODMS |
Treatment of mHRPC previously treated with docetaxel containing regimen. |
Cabozantinib |
January 2019 |
PCRS |
Treatment of advanced renal cell carcinoma (RCC) in adults following prior VEGF targeted therapy |
Carfilzomib |
October 2020 |
ODMS |
In combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy |
Carfilzomib |
September 2018 |
ODMS |
Carfilzomib, lenalidomide and dexamethasone therapy is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy |
Ceritinib |
December 2016 |
PCRS |
Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib |
Cobimetinib |
April 2018 |
PCRS |
Cobimetinib in combination with vemurafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. |
Crizotinib |
June 2014 |
PCRS |
For the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). |
Dabrafenib |
September 2014 |
PCRS |
Treatment of adult patients with unresectable or metastatic melanoma with the BRAF V600 mutation |
Dacomitinib |
November 2019 |
PCRS |
Monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations |
Daratumumab
|
June 2022 |
ODMS |
Daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adults with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant |
Daratumumab
|
October 2020 |
ODMS |
Daratumumab in combination with bortezomib and dexamethasone in adult patients with multiple myeloma who have received at least one prior therapy |
Daratumumab
|
April 2018 |
ODMS |
As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy |
Darolutamide
|
March 2022 |
PCRS |
Treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease |
Decitabine |
January 2014 |
ODMS |
Treatment of adult patients aged 65 years and above with newly diagnosed de novo or secondary AML, according to the WHO classification, who are not candidates for standard induction chemotherapy. |
Durvalumab
Durvalumab 10mg/kg Monotherapy
Durvalumab 1500mg Monotherapy
|
February 2021 |
ODMS |
As monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT). |
Encorafenib and Binimetinib |
May 2019 |
PCRS |
Treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation |
Enzalutamide |
January 2016 |
PCRS |
Treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT) in whom chemotherapy is not yet clinically indicated. |
Enzalutamide |
August 2014 |
PCRS |
The treatment of adults with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel. |
Entrectinib |
June 2022 |
PCRS |
As monotherapy for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors |
EriBULin |
January 2014 |
ODMS |
Treatment of LABC or MBC which has progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments. |
Fedratinib |
December 2022 |
PCRS |
For the treatment of disease-related splenomegaly or symptoms in adult patients with:primary myelofibrosis (PMF),post polycythaemia vera myelofibrosis (PVMF) or post essential thrombocythaemia myelofibrosis (ET MF) who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib
|
Gemtuzumab ozogamicin
|
November 2020 |
ODMS |
As combination therapy with DAUNOrubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive Acute Myeloid Leukemia (AML), except acute promyelocytic leukaemia |
Ibrutinib |
August 2016 |
PCRS |
Treatment of adult patients with chronic lymphocytic leukaemia who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo‐immunotherapy.
Treatment of adult patients with Waldenström’s macroglobulinaemia who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo‐immunotherapy.
Treatment of adult patients with relapsed or refractory mantle cell lymphoma.
|
Idelalisib
Idelalisib with Ofatumumab
|
January 2017 |
PCRS |
Monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.
In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): who have received at least one prior therapy or as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.
In combination with Ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): who have received at least one prior therapy or as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.
|
Inotuzumab |
May 2019 |
ODMS |
Monotherapy for the treatment of adults with relapsed or refractory CD22- positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+ ) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI) |
Ipilimumab |
May 2012 |
ODMS |
Treatment of adults with advanced (unresectable or metastatic) malignant melanoma. |
Ixazomib |
December 2018 |
PCRS |
Ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
|
Lenvatinib |
May 2021 |
PCRS |
As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy
|
Lenvatinib |
January 2016 |
PCRS |
Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine. |
Lorlatinib |
October 2019 |
PCRS |
As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on
(i) alectinib or ceritinib as the first ALK-targeted treatment
or
(ii) crizotinib and at least one other ALK-targeted treatment
|
Lorlatinib |
September 2022 |
PCRS |
As monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously not treated with an ALK inhibitor. |
Midostaurin |
October 2021 |
PCRS |
Midostaurin is indicated in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive
|
Mifamurtide |
March 2013 |
ODMS |
Treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection, in children, adolescents and young adults. |
Mogamulizumab |
May 2023 |
ODMS |
As monotherapy for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy. |
nab-PAClitaxel |
February 2016 |
ODMS |
nab-PACLitaxel in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. |
Neratinib |
March 2022 |
PCRS |
Extended adjuvant treatment of adults with early-stage hormone receptorpositive,HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago. |
Nintedanib Therapy |
February 2017 |
PCRS |
In combination with docetaxel for the treatment of adult patients with locally advanced, metastatic of stage IIIB or IV, or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. |
Niraparib |
April 2023 |
PCRS |
As monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. |
Niraparib |
March 2021 |
PCRS |
As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in response (complete response or partial response) to platinum-based chemotherapy |
Nivolumab |
September 2023 |
ODMS |
For the adjuvant treatment of oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. |
Nivolumab |
July 2023 |
ODMS |
In combination with fluoropyrimidine and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell programmed death ligand 1 (PD-L1) expression ≥1%. |
Nivolumab 240mg
Nivolumab 480mg
|
February 2021 |
ODMS |
As monotherapy for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection |
Nivolumab |
May 2018 |
ODMS |
As monotherapy for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy
|
Nivolumab |
September 2018 |
ODMS |
As monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults
|
Nivolumab 240mg
Nivolumab 480mg
|
October 2017 |
ODMS |
As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults
As monotherapy for the treatment of advanced renal cell carcinoma (RCC) after prior therapy in adults
As monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin
|
Nivolumab Ipilimumab |
June 2023 |
ODMS |
In combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer (MSI-HmCRC) after prior fluoropyrimidine-based combination chemotherapy.
|
Nivolumab Ipilimumab |
April 2023 |
ODMS |
Nivolumab combination with ipilimumab for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma
|
Nivolumab Ipilimumab |
March 2022 |
ODMS |
Nivolumab and ipilimumab plus PEMEtrexed and CISplatin therapy for the first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.
|
Nivolumab Ipilimumab |
March 2022 |
ODMS |
Nivolumab and ipilimumab plus PEMEtrexed and CARBOplatin therapy for the first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation
|
Nivolumab Ipilimumab |
March 2022 |
ODMS |
Nivolumab and ipilimumab plus CARBOplatin and PACLItacel therapy for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.
|
Nivolumab Ipilimumab |
February 2021 |
ODMS |
Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate-/poor-risk advanced renal cell carcinoma
|
Nivolumab Ipilimumab |
October 2017 |
ODMS |
Nivolumab in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults
|
Obinutuzumab |
August 2015 |
ODMS |
In combination with chlorambucil for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy. |
Obinutuzumab |
November 2017 |
ODMS |
Obinutuzumab in combination with bendamustine is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.
|
Obinutuzumab |
November 2017 |
ODMS |
Obinutuzumab maintenance therapy is indicated in patients with follicular lymphoma (FL) who have responded to induction treatment with obinutuzumab and bendamustine or have stable disease
|
Obinutuzumab |
May 2019 |
ODMS |
Obinutuzumab, in combination with chemotherapy, followed by maintenance treatment in patients achieving a response, for previously untreated advanced follicular lymphoma (FL).
|
Olaparib Tablets |
September 2023 |
ODMS |
In combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.
|
Olaparib Tablets |
March 2023 |
PCRS |
As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.
|
Olaparib Tablets |
December 2020 |
PCRS |
Maintenance treatment of adult patients withadvanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic)
high grade epithelial ovarian cancer fallopian tube cancer primary peritoneal cancer who are in response (complete response or partial response) following completion of first‐line platinum based chemotherapy.
|
Olaparib Tablets |
November 2017 |
PCRS |
As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed BRCA-mutated ovarian cancer (including fallopian tube or primary peritoneal) who are in response (complete response or partial response) to platinum-based chemotherapy
|
Osimertinib |
July 2020 |
PCRS |
Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)
|
Osimertinib |
October 2020 |
PCRS |
First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
|
Palbociclib |
June 2018 |
PCRS |
Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor
Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy
|
Pembrolizumab 200mg Monotherapy
Pembrolizumab 400mg Monotherapy
|
June 2016
|
ODMS
|
As monotherapy for the treatment of adults with unresectable or advanced melanoma
For the treatment of ipilimumab-refractory patients with unresectable or advanced metastatic melanoma
|
Pembrolizumab 200mg Monotherapy
Pembrolizumab 400mg Monotherapy
|
April 2018
|
ODMS
|
First-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a ≥50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.
|
Pembrolizumab 200mg Monotherapy
Pembrolizumab 400mg Monotherapy
|
November 2018
|
ODMS
|
As monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) who are transplant-ineligible and have failed brentuximab vedotin
|
Pembrolizumab
|
June 2023
|
ODMS
|
Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy, for the first line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with CPS≥10
|
Pembrolizumab 200mg
Pembrolizumab 400mg
|
April 2023
|
ODMS
|
First-line treatment of metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults.
|
Pembrolizumab 200mg Monotherapy
Pembrolizumab 400mg Monotherapy
|
February 2022
|
ODMS
|
As monotherapy for the treatment of adult patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option
|
Pembrolizumab 200mg
|
December 2021
|
ODMS
|
As monotherapy for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1
|
Pembrolizumab 400mg
|
December 2021
|
ODMS
|
As monotherapy for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1
|
Pembrolizumab
|
December 2021
|
ODMS
|
Pembrolizumab is indicated, in combination with CARBOplatin and 5-fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.
|
Pembrolizumab
|
December 2021
|
ODMS
|
Pembrolizumab is indicated, in combination with CISplatin and 5-fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.
|
Pembrolizumab 200mg
Pembrolizumab 400mg
|
May 2021
|
ODMS
|
As monotherapy for the adjuvant treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection
|
Pembrolizumab
|
February 2021
|
ODMS
|
In combination with pemetrexed and carboplatin chemotherapy, is indicated for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.
|
Pembrolizumab
|
February 2021
|
ODMS
|
In combination with pemetrexed and cisplatin chemotherapy, is indicated for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.
|
Pembrolizumab 200mg
Pembrolizumab 400mg
|
February 2021
|
ODMS
|
As monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy
|
Pembrolizumab 200mg
Pembrolizumab 400mg
|
February 2021
|
ODMS
|
As monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy whose tumours express PD-L1 with a combined positive score (CPS) ≥10
|
Pembrolizumab
|
February 2021
|
ODMS
|
In combination with carboplatin and paclitaxel for the first-line treatment of patients with metastatic squamous Non-Small Cell Lung Cancer (NSCLC)
|
Pertuzumab |
February 2014 |
ODMS |
Treatment of adult patients with HER2- positive MBC or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease |
Pertuzumab |
July 2020 |
ODMS |
Pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence |
Pertuzumab/ trastuzumab (Phesgo®) |
December 2022 |
ODMS |
Use in combination with chemotherapy as: neo-adjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. |
Pertuzumab/ trastuzumab (Phesgo®) |
December 2022 |
ODMS |
Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. |
Pixantrone |
August 2015 |
ODMS |
Monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lymphomas (NHL). |
Polatuzumab Vedotin |
December 2021 |
ODMS |
In combination with bendamustine and riTUXimab for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant |
Pomalidomide |
February 2016 |
PCRS |
In combination with dexamethasone in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy |
Pomalidomide |
December 2022 |
PCRS |
Pomalidomide in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment including lenalidomide. |
Ponatinib |
December 2016 |
PCRS |
Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation
Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
|
Radium 223 |
May 2015 |
ODMS |
Treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases |
Regorafenib |
April 2015 |
PCRS |
Treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy Treatment of adult patients Unresectable or metastatic gastrointestinal stromal tumours (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib. |
Ribociclib |
February 2019 |
PCRS |
Treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine-based therapy in combination with an aromatase inhibitor.
|
Ruxolitinib |
February 2014 |
PCRS |
The treatment of disease-related splenomegaly or symptoms in adult patients with:
- Primary myelofibrosis (chronic idiopathic myelofibrosis)
- Post polycythaemia vera myelofibrosis
- Post essential thrombocythaemia myelofibrosis
|
Siltuximab |
August 2015 |
ODMS |
Treatment of adult patients with Multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus 8 (HHV-8) negative. |
Talazoparib |
May 2021 |
PCRS |
Talazoparib is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy or be considered unsuitable for endocrine-based therapy. |
Teysuno |
February 2013 |
PCRS |
Treatment of advanced gastric cancer when given in combination with cisplatin |
Tisagenlecleucel |
July 2021 |
ODMS |
Treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse |
Tisagenlecleucel |
July 2021 |
ODMS |
Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy |
Tivozanib |
October 2019 |
PCRS |
Tivozanib for the first line treatment of adult patients with advanced renalcell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC |
Trametinib |
April 2018 |
PCRS |
Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. |
Trametinib |
December 2021 |
PCRS |
Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection. |
Trastuzumab Emtansine |
August 2015 |
ODMS |
Treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.
Patients should have either:
- Received prior therapy for locally advanced or metastatic disease, or
- Developed disease recurrence during or within six months of completing adjuvant therapy.
|
Trastuzumab Emtansine |
December 2021 |
ODMS |
As a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy
|
Trifluridine and Tipracil (Lonsurf®) Therapy |
February 2017 |
PCRS |
Treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.
|
Vandetanib |
June 2014 |
PCRS |
The treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. |
Vemurafenib |
March 2013 |
PCRS |
Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma |
Venetoclax |
March 2022 |
PCRS |
In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) |
Venetoclax |
July 2020 |
PCRS |
In combination with rituximab is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy |
Venetoclax |
December 2018 |
PCRS |
Treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor
Treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor
|
Vismodegib |
November 2017 |
PCRS |
Treatment of adult patients with Symptomatic metastatic basal cell carcinoma (MBCC),
Treatment of adult patients with Local advanced basal cell carcinoma inappropriate for surgery or radiotherapy.
|
Vxyeos liposomal® (DAUNOrubicin and cytarabine)
Induction Therapy
Consolidation Therapy
|
04 February 2021 |
ODMS |
For the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
|
Zanubrutinib
|
September 2023 |
PCRS |
As monotherapy
- for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who are treatment naïve and have del(17p) and/or TP53-mutated positive disease
for the treatment of adult patients with chronic lymphocytic leukaemia with relapsed and/or refractory disease following at least one line of prior therapy
|
Zanubrutinib
|
May 2022 |
PCRS |
For the treatment of for adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy, or as first-line treatment for patients unsuitable for chemo-immunotherapy.
|